Mon–Thu 8–18, Fri 8–16
Information on ongoing free drug trials that may need new subjects
Clinical drug trials aim to find better cancer treatments. Docrates Cancer Center provides an opportunity for cancer researchers, research institutions and pharmaceutical companies to perform clinical studies as part of the normal activities of the hospital. Studies are always performed under the close supervision of the relevant authorities.
Appointments with Docrates Cancer Center specialists are available without referral, which means that cancer patients from all parts of Finland have the opportunity to participate in clinical studies at Docrates. Such studies can allow participants to benefit from the newest treatments for several years before they become available at a pharmacy.
Docrates Cancer Center works actively to allow all cancer patients seeking new treatments to participate in clinical studies and receive investigational treatments if no curative treatment is available for their condition.
An oncologist at Docrates Cancer Center can, at your request, search public databases for clinical trials in any geographical area that could be suitable for you. This may be an alternative if there is no established treatment available for your cancer or condition, or if they have already been used, or if the doctor knows of a promising investigational medicinal product that is not yet available outside clinical trials. Read more.
Henna Lundenius, Research Coordinator
tel.+358 50 500 1895
tel. +358 10 773 2000
e-mail henna.lundenius(a)docrates.com.
Tuomo Alanko, specialist in oncology and chemotherapy as well as clinical drug trials, has been a part of the skilled team of Docrates Cancer Center since 2009. Tuomo, whose journey took him from cell biology research to oncology, knows that cancer can be a clever opponent. This is why it is important to constantly seek and study new treatments and cures.
Clinical drug trials
Docrates Cancer Center
Research Coordinator
+358 50 500 1895
Clinical drug trials
Docrates Cancer Center
Research Coordinator
+358 50 500 1856
New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...
Read more
With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...
On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....
Breast cancer is a serious disease that requires individual care and expertise. As part of cancer treatment, the patient may...
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00
